Related Experiment Video
Updated: Jun 14, 2026

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Relation between LRG1 and CD4+ T cells, cognitive impairment and neurological function in patients with acute
Xiao Cheng1,2, Hongen Wei1,2, Yi Liu1
1Department of Neurology, The Fifth Clinical Medical College of Shanxi Medical University (Fifth Hospital of Shanxi Medical University), Taiyuan, 030009, China.
Insights
Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels correlate with specific T cell populations and predict cognitive impairment and poor neurological recovery in acute ischemic stroke patients. Higher LRG1 indicates worse outcomes.
Area of Science:
- Neuroscience
- Immunology
- Cardiovascular Medicine
Background:
- Acute ischemic stroke (AIS) poses significant challenges to neurological function and cognitive health.
- T cell subsets, including Th17, Th2, and regulatory T cells (Tregs), play critical roles in the inflammatory response following stroke.
- Leucine-rich alpha-2 glycoprotein 1 (LRG1) is a protein implicated in various biological processes, but its role in AIS is not fully understood.
Purpose of the Study:
- To investigate the association between LRG1 levels and CD4+ T cell subsets in patients with AIS.
- To determine the relationship between LRG1 and cognitive impairment and neurological function recovery post-AIS.
Main Methods:
- Plasma LRG1 concentrations were measured using ELISA in 175 AIS patients at multiple time points (baseline, day 1, day 7, month 1, and month 3).
- T cell subsets (Th17, Th2, Treg) were analyzed in relation to LRG1 levels.
- Cognitive function and neurological status were assessed at 3 months post-stroke.
Main Results:
- LRG1 levels showed a negative correlation with Th2 and Treg cells and a positive correlation with Th17 cells (p < 0.05).
- LRG1 concentrations exhibited a dynamic pattern, increasing from baseline to day 1, then decreasing through month 3 (p < 0.001).
- Elevated LRG1 levels at all measured time points were significantly associated with the presence of cognitive impairment and poorer neurological function at 3 months (p < 0.05).
Conclusions:
- LRG1 is significantly associated with altered T cell profiles, specifically decreased Th2 and Treg cells and increased Th17 cells, in AIS patients.
- LRG1 serves as a potential biomarker for predicting cognitive impairment and suboptimal neurological recovery following acute ischemic stroke.
- These findings highlight LRG1's role in the immunopathology of AIS and its implications for patient outcomes.
Abstract:
Objective: To assess the relationship between LRG1 and CD4+ T cells, cognitive impairment and neurological function in acute ischemic stroke (AIS). Methods: Plasma LRG1 was detected by ELISA in 175 patients with AIS at baseline, day (D) 1, D7, month (M) 1 and M3. Results: LRG1 was negatively related to Th2 and Treg cells and positively linked to Th17 (all p < 0.05). LRG1 increased from baseline to D1, then decreased until M3 (p < 0.001). LRG1 at each assessment point was increased in patients with cognitive impairment or poor neurological function at M3 versus those without (all p < 0.05). Conclusion: LRG1 is linked to decreased Th2 and Tregs, increased Th17, cognitive impairment and nonideal neurological function recovery in patients with AIS.
More Related Videos
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction

